Neoadjuvant Vidutolimod (Vidu) and Nivolumab (Nivo) Results in MPR and Immune Activation in High-Risk Resectable Melanoma (MEL): Final Phase II Clinical Trial Results.
Nivolumab;Vidutolimod
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Neoadjuvant Vidutolimod (Vidu) and Nivolumab (Nivo) Results in MPR and Immune Activation in High-Risk Resectable Melanoma (MEL): Final Phase II Clinical Trial Results. ### Output: Nivolumab;Vidutolimod